Study on the Effect of Oral Diammonium Glycyrrhizinate in Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy

Starting soon · Phase 2/Phase 3

Conditions studied: Patients With Large B-cell Lymphoma Receiving CAR-T Cell Therapy

In brief

The purpose of this study is to evaluate the effect of oral diammonium glycyrrhizinate in reducing toxicity and enhancing efficacy of CAR-T cell therapy in patients with large B-cell lymphoma. Two main questions are addressed: 1) Can oral diammonium glycyrrhizinate reduce the incidence and severity of CRS induced by CAR-T cells? 2) Can oral diammonium glycyrrhizinate synergistically increase the therapeutic efficacy of CAR-T cell therapy?

Key facts

Study ID

NCT07616271

Run by

Tongji Hospital

People needed

21

Starts

2026-05-22

Expected to finish

2030-05-31

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years.
• Patients diagnosed with large B-cell lymphoma and receiving CAR-T cell therapy.
• Adequate organ function prior to enrollment: ALT and AST ≤ 2.5 × ULN (upper limit of normal); may be extended to ≤5 × ULN in patients with liver involvement; serum total bilirubin < 34 μmol/L; creatinine clearance > 30 mL/min; cardiac ejection fraction (EF) ≥ 40%, with no pericardial effusion or significant arrhythmia; room air SpO₂ ≥ 92%.
• No central nervous system involvement of lymphoma confirmed by MRI prior to enrollment.
• Subjects of childbearing potential must agree to use highly effective contraceptive methods.
• The subject or their legal guardian must be able to understand and voluntarily sign a written informed consent form.

You may not qualify if…

• Presence of a prior malignancy (other than the disease under study) that requires ongoing systemic treatment for any other malignant tumor.
• Presence of any life-threatening disease, medical condition, or organ system dysfunction that, in the investigator's judgment, may compromise patient safety or interfere with the interpretation of safety or efficacy data.
• Current or prior central nervous system (CNS) involvement by malignancy.
• Receipt of allogeneic stem cell transplantation within 6 months prior to enrollment, or autologous stem cell transplantation within 3 months prior to enrollment; and the patient must have no signs or symptoms of graft-versus-host disease and must not be receiving immunosuppressive therapy.
• Intolerance or allergy to glycyrrhizic acid preparations.
• Patient refuses to comply with the study requirements to complete the research work.
• In the investigator's judgment, the patient is unable to complete the study or comply with the study requirements (due to administrative reasons or other reasons), or is considered unsuitable for clinical trial participation for other reasons.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.